Drug Trial Radar · NCT06388031
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Last checked: Nov 20, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Aug 9, 2024
Primary completion
Jan 10, 2027
Study completion Dec 10, 2027
Sponsor
- Lead sponsor
- Peking Union Medical College HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An exploratory phase II trial of immune checkpoint inhibitors (ICIs, anti-PD-1/anti-PD-L1) as second-line treatment with advanced non-small cell lung cancer (NSCLC) who had long-term response to first-line immunotherapy (with or without chemotherapy). This study aims to evaluate efficacy and safety of ICI rechallenge in long-term responders to prior ICI. Furthermore, it seeks to identify biomarkers capable of predicting the efficacy of immunotherapy and prognosis.
Conditions
- Non-small Cell Lung Cancer
Interventions
Immune checkpoint inhibitorDrug
Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles: * Pembrolizumab 200mg; * Tislelizumab 200mg; * Camrelizumab 200mg; * Toripalimab 240mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: 5 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.